Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of ABBV-668 ER Formulations
NCT06477926Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-668 in ulcerative colitis (UC) (7 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Started Jul 2024; status: completed.
02
Drugs
ABBV-668
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06477926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477926.